Financial Data and Key Metrics Changes - The company reported combined revenues of $11,700,000 for Q1 2025, representing a 38% increase compared to the prior year period [8][26] - Total assets improved to $70,000,000, with $50,000,000 in cash, and total liabilities decreased to $42,000,000, resulting in shareholders' equity of $51,000,000 [8][29] - Net profit for the quarter was $1,260,000, with adjusted earnings of $2,400,000 and cash flow from operations of $3,900,000 [8][26] Business Line Data and Key Metrics Changes - Revenue breakdown for Q1 2025 included $3,500,000 for Cristalos, $2,300,000 for SANKUSO, $1,400,000 for Vibativ, and $1,300,000 for Caldolor [26] - The company launched new marketing initiatives and expanded its sales force to support its FDA approved products [11][12] Market Data and Key Metrics Changes - The approval of Vibativ in China provides access to a significant pharmaceutical market, with expectations for launch later in the year [10] - The company is enhancing its presence in states with Medicaid coverage for Cristalos, contributing to its growth [14] Company Strategy and Development Direction - The company is focused on expanding its portfolio through strategic acquisitions and enhancing its marketing initiatives for existing products [32] - The management is optimistic about the positioning of Vibativ amid growing global concerns over antimicrobial resistance [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's future, citing strong performance in Q1 and positive developments in the clinical pipeline [7][31] - The company anticipates continued momentum across its approved brands and further progress in its clinical pipeline [33] Other Important Information - The company continues to hold over $53,000,000 in tax net operating loss carryforwards, primarily from prior stock option exercises [29] - The company is implementing new trading plans for board members to increase their holdings in the company [29] Q&A Session Summary - There were no questions from participants during the Q&A session, and management encouraged private discussions with shareholders if desired [35][36]